newsfilter
← Earnings
Earnings Releases·

Galectin Therapeutics — Q3 2026 Earnings Summary

Galectin Therapeutics reported a net loss of $3.6 million for the quarter ended September 30, 2026, driven by $1.6 million in research and development expenses and $1.8 million in general and administrative expenses. The company submitted its registrational Phase 3 protocol for belapectin to the FDA in the third quarter following alignment on the trial design for advanced MASH cirrhosis. Significant corporate developments included the conversion of approximately $105.8 million in debt held by Chairman Richard E. Uihlein into over 34 million shares of common stock. As of September 30, 2026, the company held $11.7 million in cash and cash equivalents, with sufficient funds to support operations through June 2027.

Company
GALECTIN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology